Delivery Order SPE2DB24D1205-SPE2DB25FCZEP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on July 25, 2025, with a contract ceiling value of $46,927.70 and a completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The order represents a single transaction within...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors with a ceiling value of $16,289.67 under firm fixed-price terms. The contract is set to be completed by August 6, 2025, with the place of performance located in Conshohocken, Pennsylvania. This is a non-set-aside, competitively awarded delivery order issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,799.84 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside contract utilizing an existing contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.54 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on August 4, 2025, with completion targeted for August 5, 2025. This non-competitive, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's larger federal pharmaceutical supply relationship. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87 and an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the government's procurement of this diabetes medication through AmerisourceBergen's existing pharmaceutical supply contracts. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections with a ceiling value of $3,648.19. This firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation and represents a routine pharmaceutical supply transaction under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections, with a contract ceiling value of $2,287.74 and an ultimate completion date of August 1, 2025. This is a firm fixed-price, non-set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive global pharmaceutical support vehicle valued through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $7,625.80. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The delivery order is scheduled for completion by August 5, 2025, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injections with a ceiling value of $2,178.54. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,134.75 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units). This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the federal healthcare supply...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZEPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 10 mg/0.5 ml pen injections in 0.5 ml quantities. This firm fixed-price delivery order, valued at $33,707.47, represents a non-competitive set-aside and is scheduled for completion by August 5, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, serving the military healthcare supply chain through DLA Medical Supply Chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceuticals, medical devices, and healthcare commodities to support military and veteran healthcare systems. The company's contract performance demonstrates its capability to fulfill federal medical supply requirements across multiple therapeutic domains, with this particular delivery supporting diabetes management medications for Defense Health Agency beneficiaries and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.7k | 8/4/25 |